Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? (RIPCORD 2)

A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.

A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).

Aperçu de l'étude

Description détaillée

The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

Type d'étude

Interventionnel

Inscription (Réel)

1100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Bristol, Royaume-Uni, BS2 8HW
        • Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust
    • Dorset
      • Bournemouth, Dorset, Royaume-Uni, BH7 7DW
        • Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
    • East Sussex
      • Brighton, East Sussex, Royaume-Uni, BN2 5BE
        • Brighton and Sussex University Hospitals NHS Trust
    • Hampshire
      • Portsmouth, Hampshire, Royaume-Uni, PO6 3LY
        • Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
      • Southampton, Hampshire, Royaume-Uni, SO16 6YD
        • Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
    • Lancashire
      • Blackburn, Lancashire, Royaume-Uni, BB2 3HH
        • Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
    • Merseyside
      • Liverpool, Merseyside, Royaume-Uni, L14 3PE
        • Liverpool Heart and Chest Hospital NHS Foundation Trust
    • Northumberland
      • Newcastle upon Tyne, Northumberland, Royaume-Uni, NE7 7DN
        • Freeman Hospital - Newcastle Hospitals
    • Nottinghamshire
      • Mansfield, Nottinghamshire, Royaume-Uni, NG17 4JL
        • King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
      • Nottingham, Nottinghamshire, Royaume-Uni, NG5 1PB
        • City Hospital - Nottingham University Hospitals NHS Trust
    • Scotland
      • Glasgow, Scotland, Royaume-Uni, G81 4DY
        • Golden Jubilee National Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Royaume-Uni, S5 7AU
        • Northern General Hospital - Sheffield Teaching Hospitals
    • Staffordshire
      • Stoke-on-Trent, Staffordshire, Royaume-Uni, ST4 6QG
        • Royal Stoke University Hospital - University Hospitals of North Midlands
    • West Midlands
      • Birmingham, West Midlands, Royaume-Uni, B15 2TH
        • Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
    • West Yorkshire
      • Wakefield, West Yorkshire, Royaume-Uni, WF1 4DG
        • Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
    • Yorkshire
      • Hull, Yorkshire, Royaume-Uni, HU16 5JQ
        • Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
      • Leeds, Yorkshire, Royaume-Uni, LS1 3EX
        • Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

· Inclusion criteria

o Outline Initial Inclusion Criteria (before entry to cath lab):

Patient scheduled for coronary angiography for the:

  • Elective investigation of known or suspected coronary artery disease OR
  • Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event

    o Outline Angiographic Inclusion Criterion (after angiography):

  • Presence of significant coronary disease defined as:

Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter.

  • Key Exclusion Criteria

    • Screening phase exclusion criteria:

      • ≤ 18 years of age
      • Previous enrolment in this trial
      • Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU)
      • Inability to provide informed consent
      • Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year
      • Non-cardiac pathology that may limit survival in the next year
      • Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery)
      • Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy
      • Hypertrophic cardiomyopathy
      • Previous coronary artery surgery of any type
      • Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45
      • Anaemia with a current measured haemoglobin of < 100
      • Angiography performed in the context of an ST elevation myocardial infarction event
      • Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block
      • Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms
      • Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory
      • Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease
      • Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning.
      • Active bleeding at the time of planned index angiography
      • Pregnant women
    • Angiographic phase exclusion criteria:

      • Single vessel occlusive coronary disease (TIMI flow <3) as sole disease
      • Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example:

        • Patient discomfort
        • Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention
        • Significant use of radiographic contrast or X-Ray exposure during the initial angiography
        • Inadequate angiographic images or failure to intubate any of the coronary vessels
        • Aorto-ostial disease that would preclude accurate assessment of FFR
        • Insufficient laboratory time
        • Uncertain availability of key clinical and trial staff
        • PW use in coronaries declared unsafe (e.g. tight or long disease)
        • PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Diagnostique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Conventional angiography
Routine angiography will be performed according to local best practice
Expérimental: Routine Measurement of FFR
Additional investigation with the measurement of FFR in all major vessels
FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
Autres noms:
  • Pressure wire assessment

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Primary Economic Outcome Measure
Délai: One year
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
One year
Primary Quality of Life Outcome Measure
Délai: One year
Patient reported quality of life at one year using the EQ-5D health questionnaire.
One year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mortalité toutes causes confondues
Délai: Un ans
Un ans
Management strategy information
Délai: Reported once: Single declaration at index procedure after randomisation
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Management strategy information
Délai: Reported once: Single declaration at index procedure after randomisation
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Reported once: Single declaration at index procedure after randomisation
Angina symptoms
Délai: One year
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
One year
Angina symptoms
Délai: One year
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
One year
Number of hospitalisation events
Délai: One year
One year
Total hospital days
Délai: One year
One year
Hospitalisation events
Délai: One year
Hospitalisation events coded as cerebro-vascular accident (CVA).
One year
Hospitalisation events
Délai: One year
Hospitalisation events coded as myocardial infarction.
One year
Hospitalisation events
Délai: One year

Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of:

  • Planned revascularisation - if declared as the index strategy.
  • All additional revascularisation events.
One year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Nicholas Curzen, BM PhD FRCP, University Hospital Southampton NHS Foundation Trust
  • Chercheur principal: Rod H Stables, MA, DM, BM BCH, FRCP, Liverpool Heart and Chest Hospital NHS Foundation Trust

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 septembre 2016

Achèvement primaire (Anticipé)

1 décembre 2019

Achèvement de l'étude (Anticipé)

1 mars 2020

Dates d'inscription aux études

Première soumission

6 juillet 2016

Première soumission répondant aux critères de contrôle qualité

1 septembre 2016

Première publication (Estimation)

8 septembre 2016

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 août 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 août 2019

Dernière vérification

1 août 2019

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner